Variant · Snv
BRAF V600R
CI-VAR-00004581Explore in graph →CIViC 16 rs121913227
Curated evidence
Evidence by cancer (9 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23237741
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Cutaneous Melanoma2 | ||||||||
| BRAF V600R | Vemurafenib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID4172An 81 year old male was diagnosed with ulcerated cutaneous melanoma of the occiput (M1c), and had undergone several local resections and radiotherapy. A metastasis was found to harbor BRAF V600R mutat… (full text at CIViC) PMID 23237741 · Klein et al., 2013 · Open in CIViC | civic |
| BRAF V600R | Dabrafenib + VemurafenibSubstitutes | Predictive | B | Does Not Support Resistance | 2 | submitted | EID8948Nine patients with BRAF V600R mutated metastatic melanoma were given dabrafenib (n=7) or vemurafenib (n=2) monotherapy as part of a compassionate access program. Five out of six radiographically asses… (full text at CIViC) PMID 23237741 · Klein et al., 2013 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available